JP2009539994A - 癌の治療のための化合物及び組成物 - Google Patents

癌の治療のための化合物及び組成物 Download PDF

Info

Publication number
JP2009539994A
JP2009539994A JP2009515473A JP2009515473A JP2009539994A JP 2009539994 A JP2009539994 A JP 2009539994A JP 2009515473 A JP2009515473 A JP 2009515473A JP 2009515473 A JP2009515473 A JP 2009515473A JP 2009539994 A JP2009539994 A JP 2009539994A
Authority
JP
Japan
Prior art keywords
composition
dose
cancer
mammal
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539994A5 (enExample
Inventor
シー． アデルマン ダニエル
ジェイ． エバンチク マルク
スドハカル アナントハ
ウィルリアム ジャコブス ジェフフレイ
エー．シルべルマン ジェフフレイ
Original Assignee
サネシス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009539994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サネシス ファーマシューティカルズ， インコーポレイテッド filed Critical サネシス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2009539994A publication Critical patent/JP2009539994A/ja
Publication of JP2009539994A5 publication Critical patent/JP2009539994A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009515473A 2006-06-12 2007-06-12 癌の治療のための化合物及び組成物 Pending JP2009539994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81283506P 2006-06-12 2006-06-12
PCT/US2007/013873 WO2007146335A2 (en) 2006-06-12 2007-06-12 Compounds and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013105196A Division JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物

Publications (2)

Publication Number Publication Date
JP2009539994A true JP2009539994A (ja) 2009-11-19
JP2009539994A5 JP2009539994A5 (enExample) 2010-07-29

Family

ID=38832517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009515473A Pending JP2009539994A (ja) 2006-06-12 2007-06-12 癌の治療のための化合物及び組成物
JP2013105196A Pending JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物
JP2015237527A Pending JP2016094434A (ja) 2006-06-12 2015-12-04 癌の治療のための化合物及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013105196A Pending JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物
JP2015237527A Pending JP2016094434A (ja) 2006-06-12 2015-12-04 癌の治療のための化合物及び組成物

Country Status (11)

Country Link
US (4) US8124773B2 (enExample)
EP (2) EP2043645A2 (enExample)
JP (3) JP2009539994A (enExample)
KR (1) KR20090021215A (enExample)
CN (2) CN104027333B (enExample)
AU (1) AU2007258280B2 (enExample)
BR (1) BRPI0713637A2 (enExample)
CA (1) CA2654876A1 (enExample)
IL (2) IL195883A0 (enExample)
MX (1) MX2008015775A (enExample)
WO (1) WO2007146335A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013209398A (ja) * 2006-06-12 2013-10-10 Sunesis Pharmaceuticals Inc 癌の治療のための化合物及び組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5317472B2 (ja) 2004-03-15 2013-10-16 サネシス ファーマシューティカルズ， インコーポレイテッド Ｓｎｓ−５９５、及びその使用方法
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
AU2008317400B2 (en) 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
RU2548031C2 (ru) * 2008-12-31 2015-04-10 Санесис Фармасьютикалз, Инк. Способ получения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты
RU2558835C2 (ru) 2009-02-27 2015-08-10 Санесис Фармасьютикалз, Инк. Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
AU2013202641B2 (en) * 2009-09-04 2015-07-23 Sunesis Pharmaceuticals, Inc. Stable sns-595 compositions and methods of preparation
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034559A1 (en) * 1994-06-14 1995-12-21 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JPH09221424A (ja) * 1995-12-13 1997-08-26 Dainippon Pharmaceut Co Ltd 抗腫瘍剤
US20050203120A1 (en) * 2004-03-15 2005-09-15 Adelman Daniel C. SNS-595 and methods of using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5078966A (en) 1990-08-14 1992-01-07 Nalco Chemical Company Carbohydrazide to prevent hydrogen blistering and corrosion of metal surfaces in contact with refinery overhead condensates
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
DE69813194T2 (de) 1997-01-13 2004-02-05 Kudos Pharmaceuticals Ltd. Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
JP2001523977A (ja) * 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
CA2363621A1 (en) * 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
WO2002036171A1 (en) * 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US20030016887A1 (en) * 2001-07-18 2003-01-23 Fu-Long Su Receiving bag with seal opening and sealing clip
WO2004085418A2 (en) 2003-03-24 2004-10-07 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
US7387499B2 (en) 2004-08-13 2008-06-17 Gateway Inc. System and method for testing the operation of a cooling fan
KR20080041298A (ko) 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
HUE026693T2 (hu) * 2006-08-02 2016-07-28 Sunesis Pharmaceuticals Inc (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére
AU2008317400B2 (en) 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034559A1 (en) * 1994-06-14 1995-12-21 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JPH09221424A (ja) * 1995-12-13 1997-08-26 Dainippon Pharmaceut Co Ltd 抗腫瘍剤
US20050203120A1 (en) * 2004-03-15 2005-09-15 Adelman Daniel C. SNS-595 and methods of using the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5009011464; ＨＯＣＨ，Ｕ．，ＥＴ　ＡＬ．: '"ＣＹＰ４５０　Ｉｎｈｉｂｉｔｉｏｎ，Ｉｎｄｕｃｔｉｏｎ，Ｍｅｔａｂｏｌｉｓｍ，ａｎｄ　Ｒｏｕｔｅｓ　ｏｆ　Ｅｌｉｍｉｎａｔｉｏｎ　ｏｆ　ＳＮＳ-５９５，ａ　Ｎｏｖｅｌ　Ｃｅｌｌ　Ｃｙｃｌｅ' ＡＡＣＲ-ＮＣＩ-ＥＯＲＴＣ　ｉｎｔｅｒｎａｔｉｏｎａｌ，　Ｐｏｓｔｅｒ　Ｓｅｓｓｉｏｎ　Ｃ , 20051117 *
JPN5009011465; ＥＢＢＩＮＧＨＡＵＳ，Ｓ．，ＥＴ　ＡＬ．: '"Ａ　Ｐｈａｓｅ　Ｉ　ｔｒｉａｌ　ｏｆ　ｗｅｅｋｌｙ　ＳＮＳ-５９５　ｉｎ　ｐａｔｉｅｎｔｓ　（ＰＴＳ）　ｗｉｔｈ　ｒｅｆｒａｃｔｏｒｙ　ｃａｎｃｅｒ"' ＰＲＯＣＥＥＤＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＮＮＵＡＬ　ＭＥＥＴＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ＶＯＬ．４７, 20060401, Ｐ．６８５，＃２９１３ *
JPN5009011466; ＨＵＲＷＩＴＺ，Ｈ．，ＥＴ　ＡＬ．: '"ＳＮＳ-５９５　ｄｅｍｏｎｓｔｒａｔｅｓ　Ｃｌｉｎｉｃａｌ　Ａｃｔｉｖｉｔｙ　ａｎｄ　Ｄｏｓｅ　Ｐｒｏｐｏｒｔｉｏｎａｌ　Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ　（ＰＫ）　ｉｎ　Ｔｗｏ　Ｐｈａｓｅ　１　Ｃ' ＡＳＣＯ　Ａｎｎｕａｌ　Ｍｅｅｔｉｎｇ，Ｇｅｏｒｇｉａ　Ｗｏｒｌｄ　Ｃｏｎｇｒｅｓｓ　Ｃｅｎｔｅｒ，Ａｔｌａｎｔａ，Ｇｅｏｒｇｉａ Ａｂｓｔｒａｃｔ　Ｎｕｍｂｅｒ：　３０６２, 20060604 *
JPN5009011467; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　Ｓｔｒｕｃｔｕｒｅ-Ａｃｔｉｖｉｔｙ　Ｒｅｌａｔｉｏｎｓｈｉｐｓ　ｏｆ　Ｎｏｖｅｌ　７-Ｓｕｂｓｔｉｔｕｔｅｄ　１，４-Ｄｉｈｙｄｒｏ-４-ｏｘｏ-１-（２-ｔｈｉａｚｏ' ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ ＶＯＬ．４７，ＮＯ．８, 20040101, ＰＰ．２０９７-２１０９ *
JPN6012056530; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｓｔｒｕｃｔｕｒｅ-ａｃｔｉｖｉｔｙ　ｒｅｌａｔｉｏｎｓｈｉｐｓ　ｏｆ　ｎｏｖｅｌ　７-ｓｕｂｓｔｉｔｕｔｅｄ　１，４-ｄｉｈｙｄｒｏ-４-ｏｘｏ-１-（２-ｔｈｉａｚｏ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ ＶＯＬ．１４，ＮＯ．１２, 20040621, ＰＰ．３１８９-３１９３ *
JPN6012056532; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｐｒａｃｔｉｃａｌ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　（３Ｓ，４Ｓ）-３-ｍｅｔｈｏｘｙ-４-ｍｅｔｈｙｌａｍｉｎｏｐｙｒｒｏｌｉｄｉｎｅ"' ＴＥＴＲＡＨＥＤＲＯＮ　ＡＳＹＭＭＥＴＲＹ ＶＯＬ．１２，ＮＯ．２１, 20011126, ＰＰ．２９８９-２９９７ *
JPN6012056533; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｅｆｆｉｃｉｅｎｔ　ｓｔｅｒｅｏｓｐｅｃｉｆｉｃ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　（Ｓ，Ｓ）-３-ｍｅｔｈｏｘｙ-４-ｍｅｔｈｙｌａｍｉｎｏｐｙｒｒｏｌｉｄｉｎｅ"' ＴＥＴＲＡＨＥＤＲＯＮ　ＡＳＹＭＭＥＴＲＹ ＶＯＬ．１２，ＮＯ．１２, 20010716, ＰＰ．１７９３-１７９９ *
JPN6012056535; ＣＨＩＢＡ，Ｋ．，ＥＴ　ＡＬ．: '"ＰＲＡＣＴＩＣＡＬ　ＳＹＮＴＨＥＳＩＳ　ＯＦ　ＡＧ-７３５２，　ＡＮ　ＯＰＴＩＣＡＬＬＹ　ＡＣＴＩＶＥ　ＮＥＷ　ＡＮＴＩＴＵＭＯＲ　ＡＧＥＮＴ"' ＢＯＯＫ　ＯＦ　ＡＢＳＴＲＡＣＴＳ　２１８ＴＨ　ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ　（ＡＣＳ）　ＮＡＴＩＯＮＡＬ　ＭＥＥＴＩＮＧ　ＡＵＧＵＳＴ　２２-２６，１９９９ , 19990101, Ｐ．３，ｐａｒａｇｒａｐｈ　１２７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013209398A (ja) * 2006-06-12 2013-10-10 Sunesis Pharmaceuticals Inc 癌の治療のための化合物及び組成物

Also Published As

Publication number Publication date
JP2013209398A (ja) 2013-10-10
WO2007146335A2 (en) 2007-12-21
CA2654876A1 (en) 2007-12-21
US20100029708A1 (en) 2010-02-04
US20150150858A1 (en) 2015-06-04
US20120245198A1 (en) 2012-09-27
BRPI0713637A2 (pt) 2012-10-23
US8124773B2 (en) 2012-02-28
EP2043645A2 (en) 2009-04-08
KR20090021215A (ko) 2009-02-27
AU2007258280B2 (en) 2013-05-02
IL195883A0 (en) 2009-09-01
US8765954B2 (en) 2014-07-01
CN104027333B (zh) 2017-05-17
US20170101404A1 (en) 2017-04-13
CN104027333A (zh) 2014-09-10
CN101505753A (zh) 2009-08-12
AU2007258280A1 (en) 2007-12-21
IL243294A0 (en) 2016-02-29
WO2007146335A3 (en) 2009-02-12
CN101505753B (zh) 2014-05-21
MX2008015775A (es) 2009-04-17
US9676774B2 (en) 2017-06-13
JP2016094434A (ja) 2016-05-26
EP2354138A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
JP2016094434A (ja) 癌の治療のための化合物及び組成物
US9724338B2 (en) Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20180098975A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN105596320A (zh) 癌症治疗用选择性ep4受体拮抗物质
US20200002316A1 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
EP1931339B1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
CA2620915C (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242B2 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2016210657A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130730